Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Basic Trial Information

Objectives

Primary

1. Compare the efficacy of nurse-delivered WRITE Symptoms© and self-directed WRITE Symptoms© vs usual care interventions in improving target symptom representations (i.e., decreases in symptom severity, symptom-related distress, and symptom consequences as measured by the Symptom Representation Questionnaire [SRQ]) in patients with recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.

Secondary

1. Compare the efficacy of nurse-delivered WRITE Symptoms© vs self-directed WRITE Symptoms© vs usual care interventions in improving target symptom representations in these patients at 4 weeks.
2. Compare the efficacy of nurse-delivered WRITE Symptoms© vs self-directed WRITE Symptoms© vs usual care interventions in improving target symptom controllability in these patients at 4, 8, and 12 weeks.
3. Compare the efficacy of nurse-delivered WRITE Symptoms© vs self-directed WRITE Symptoms© vs usual care interventions in improving indicators of quality of life (QOL) of these patients as measured by the FACT-O and the CES-Depression inventory short form at 4, 8, and 12 weeks.
4. Compare the efficacy of nurse-delivered WRITE Symptoms© vs self-directed WRITE Symptoms© vs usual care interventions in improving communication with health care providers about symptoms, implementation of new symptom management strategies (health care provider recommended as well as patient-initiated changes), and perceived effectiveness of strategies (health care provider recommended as well as patient-initiated changes) in these patients at 4, 8, and 12 weeks.
5. Compare the efficacy of nurse-delivered WRITE Symptoms© vs self-directed WRITE Symptoms© vs usual care interventions in improving patient-related barriers to symptom management as measured by the Symptom Management Barriers Questionnaire at 4, 8, and 12 weeks.

Exploratory

1. Compare trajectories of change for overall symptom severity in patients undergoing nurse-delivered WRITE Symptoms© vs self-directed WRITE Symptoms© vs usual care interventions using monthly assessments to explore potential long-term effects of the WRITE Symptoms© interventions.
2. Compare trajectories of change for QOL of patients undergoing nurse-delivered WRITE Symptoms© vs self-directed WRITE Symptoms© vs usual care interventions using monthly assessments to explore potential long-term effects of the WRITE Symptoms© interventions.
3. Compare trajectories of change for symptom severity, distress, communication, and implementation of new strategies for non-targeted symptoms in patients undergoing nurse-delivered WRITE Symptoms© vs self-directed WRITE Symptoms© vs usual care interventions using monthly assessments to explore whether patients are able to generalize the symptom management approaches taught in WRITE Symptoms© interventions to their other non-targeted symptoms.
4. Explore whether changes in symptom representations mediate changes in QOL of these patients at 8 and 12 weeks.
5. Explore whether effects of the WRITE Symptoms© interventions on primary and secondary endpoints at 8 and 12 weeks differ based on the following patient characteristics assessed at baseline: age, education, and ethnicity; depression as measured by the CES-D short form; trait anxiety as measured by the STAI; optimism as measured by the LOT-R; social support as measured by the ISEL; and symptom severity as measured by the SRQ.

Entry Criteria

Disease Characteristics:

• Diagnosis of ovarian, fallopian tube, or primary peritoneal cancer that has recurred or persisted following primary therapy
  • Active disease or current treatment are not required

• Must be experiencing ≥ 3 symptoms associated with ovarian cancer or cancer treatment, including, but not limited to, any of the following:
  • Abdominal bloating or cramping
  • Nausea, vomiting, or diarrhea
  • Constipation
  • Anorexia
  • Anxiety
  • Depression
  • Dizziness
  • Drowsiness
  • Dry mouth
  • Fatigue
  • Headaches
  • Hair loss
  • Hot flashes
  • Memory concerns
  • Mood swings
  • Mouth sores
  • Pain
  • Peripheral neuropathies
  • Sexuality concerns
  • Sleep disturbances
  • Shortness of breath
  • Skin rash or palmar-plantar erythrodysesthesia
  • Urinary problems
  • Weight gain or loss

Prior/Concurrent Therapy:

• See Disease Characteristics
• Concurrent treatment on other clinical trials allowed

Patient Characteristics:

• GOG performance status 0-2
• Able to read and write English
• Access to computer and the Internet required

Expected Enrollment

Outcomes

Severity, distress, consequences, and control of symptoms as measured by the Symptom Representation Questionnaire at baseline and at 4, 8, and 12 weeks

Health-related quality of life as measured by the FACT-O at baseline, at 4, 8, and 12 weeks, and then every 4 weeks for 1 year
Depressive symptoms as measured by the CES-D short form at baseline, at 4, 8, and 12 weeks, and then every 4 weeks for 1 year
Barriers to symptom management as measured by the Symptom Management Barriers Questionnaire at baseline and at 4, 8, and 12 weeks
Communication with health care providers as measured at baseline and at 4, 8, and 12 weeks
Change, use, and effectiveness of symptom management strategies as measured at baseline and at 4, 8, and 12 weeks
Mini-assessment of non-target symptoms as measured at baseline, at 4, 8, and 12 weeks, and then every 4 weeks for 1 year

Outline

This is a multicenter study. Patients are stratified according to race/ethnicity (non-Hispanic white vs Hispanic or non-white). Patients are randomized to 1 of 3 intervention arms.

• Arm I (nurse-delivered intervention): Patients are given password-protected access to their own web-based message board to communicate with a research nurse. The nurse leads the patient through the WRITE Symptoms© intervention module comprising representational assessment; exploring concerns/misconceptions/gaps/confusions; creating conditions for conceptual change; introducing new information, goal setting, and development of a symptom management plan; and summary via asynchronous postings to the patient's message board. Patients work through 3 selected symptoms using the nurse-delivered WRITE Symptoms© intervention module over approximately 4 weeks. Two weeks later, the patient's symptom management strategy and their desire to make further changes are evaluated by additional interaction with the nurse via the message board. The nurse will encourage the patient to try new selected strategies, continue with effective strategies, and work with local health care providers in an ongoing process to improve symptom management. Patients are given access to a resource guide that includes self-care guides for 26 symptoms. They are encouraged to use the same process taught for their 3 selected symptoms for any other symptoms that arise after the course of the intervention.

• Arm II (self-directed intervention): Patients are given password-protected access to an interactive web-based computer program that will lead them through a modified WRITE Symptoms© intervention module (comprising the same elements as in arm I) without guidance and individualized recommendations from a nurse. Patients work through 3 selected symptoms using the WRITE Symptoms© intervention module over approximately 4 weeks. Two weeks later, patients are prompted by the computer program to respond to questions about their symptom management strategy and their desire to make further changes. The program will generate an encouragement for the patient to try new selected strategies, continue with effective strategies, and continue the new approach to symptom management with local health care providers in an ongoing process to improve symptom management. Patients are given access to a resource guide that includes self-care guides for 26 symptoms. They are encouraged to use the same process taught for their 3 selected symptoms for any other symptoms that arise after the course of the intervention.

• Arm III (usual care): Patients are given password-protected access to online questionnaires. Patients are prompted monthly to complete online questionnaires. Patients receive standard symptom management from their local health care providers.

In all arms, patients complete online questionnaires to assess outcome measures at baseline, at 4, 8, and 12 weeks, and then every 4 weeks for 1 year.

Trial Contact Information

Trial Lead Organizations

Gynecologic Oncology Group

Heidi Donovan, RN, PhD, Protocol chair		Ph: 412-624-2699

U.S.A.
California
	Los Angeles
	Jonsson Comprehensive Cancer Center at UCLA
		Clinical Trials Office - Jonsson Comprehensive Cancer Center at UCLA	Ph:  888-798-0719
	Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
		Ilana Cass	Ph:  310-423-3277
	Mountain View
	Palo Alto Medical Foundation
		Albert Pisani	Ph:  650-934-7000
Connecticut
	New Britain
	George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
		Clinical Trials Office - George Bray Cancer Center	Ph:  860-224-5660
Hawaii
	Honolulu
	Cancer Research Center of Hawaii
		Clinical Trials Office - Cancer Research Center of Hawaii	Ph:  808-586-2979
	Kapiolani Medical Center for Women and Children
		Michael Carney, MD	Ph:  808-983-6090
	MBCCOP - Hawaii
		Michael Carney, MD	Ph:  808-983-6090
	Queen's Cancer Institute at Queen's Medical Center
		Michael Carney, MD	Ph:  808-983-6090
Illinois
	Decatur
	Decatur Memorial Hospital Cancer Care Institute
		Clinical Trials Office - Decatur Memorial Hospital Cancer Care Institute	Ph:  217-876-4750
	Springfield
	Regional Cancer Center at Memorial Medical Center
		Clinical Trials Office - Regional Cancer Center at Memorial Medical Center	Ph:  217-788-4233
	Urbana
	CCOP - Carle Cancer Center
		Clinical Trials Office - CCOP - Carle Cancer Center	Ph:  800-446-5532
Indiana
	Elkhart
	Elkhart Clinic, LLC
		Michael Rodriguez	Ph:  574-296-3200
	Elkhart General Hospital
		Michael Rodriguez	Ph:  574-294-2621
	Michiana Hematology-Oncology, PC - Elkhart
		Michael Rodriguez	Ph:  574-389-0414
	Kokomo
	Howard Community Hospital
		Michael Rodriguez	Ph:  765-453-8571
	La Porte
	Center for Cancer Therapy at LaPorte Hospital and Health Services
		Michael Rodriguez	Ph:  219-326-2683
	Mishawaka
	Michiana Hematology-Oncology, PC - South Bend
		Michael Rodriguez	Ph:  574-234-5123
	Saint Joseph Regional Medical Center
		Michael Rodriguez	Ph:  574-237-7111
	Plymouth
	Michiana Hematology Oncology PC - Plymouth
		Michael Rodriguez	Ph:  574-936-2585
	South Bend
	CCOP - Northern Indiana CR Consortium
		Michael Rodriguez	Ph:  574-647-7370 800-284-7370
	Memorial Hospital of South Bend
		Clinical Trials Office - Memorial Hospital of South Bend	Ph:  800-284-7370
	Michiana Hematology-Oncology, PC - South Bend
		Michael Rodriguez	Ph:  574-234-5123
	Westville
	Michiana Hematology Oncology PC - La Porte
		Michael Rodriguez	Ph:  219-324-1790
Iowa
	Clive
	Medical Oncology and Hematology Associates - West Des Moines
		Robert Behrens	Ph:  515-875-9713
	Mercy Cancer Center - West Lakes
		Robert Behrens	Ph:  515-643-8206 888-221-4849
	Des Moines
	CCOP - Iowa Oncology Research Association
		Robert Behrens	Ph:  515-244-7586 888-244-6061
	John Stoddard Cancer Center at Iowa Lutheran Hospital
		Clinical Trials Office - John Stoddard Cancer Center at Iowa Lutheran Hospital	Ph:  515-241-8704
	John Stoddard Cancer Center at Iowa Methodist Medical Center
		Clinical Trials Office - John Stoddard Cancer Center at Iowa Methodist Medical Center	Ph:  515-241-6727
	Medical Oncology and Hematology Associates at John Stoddard Cancer Center
		Robert Behrens	Ph:  515-282-2921
	Medical Oncology and Hematology Associates at Mercy Cancer Center
		Robert Behrens	Ph:  515-643-8740
	Mercy Cancer Center at Mercy Medical Center - Des Moines
		Robert Behrens	Ph:  515-643-8206 888-221-4849
	Iowa City
	Holden Comprehensive Cancer Center at University of Iowa
		Cancer Information Service	Ph:  800-237-1225
	West Des Moines
	Mercy Cancer Center at Mercy Medical Center - Des Moines
		Robert Behrens	Ph:  515-643-8206 888-221-4849
	Methodist West Hospital
		Robert Behrens	Ph:  515-343-1000
Kansas
	Overland Park
	Menorah Medical Center
		Rakesh Gaur, MD	Ph:  913-948-5588
	Saint Luke's Hospital - South
		Rakesh Gaur, MD	Ph:  913-948-5588
	Prairie Village
	CCOP - Kansas City
		Rakesh Gaur, MD	Ph:  913-948-5588
Maryland
	Baltimore
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
		Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Center at John Hopkins	Ph:  410-955-8804
			Email: jhcccro@jhmi.edu
Massachusetts
	Worcester
	UMASS Memorial Cancer Center - University Campus
		Susan Zweizig, MD	Ph:  508-334-1160
Michigan
	Detroit
	Barbara Ann Karmanos Cancer Institute
		Clinical Trials Office - Barbara Ann Karmanos Cancer Institute	Ph:  313-576-9363
	Escanaba
	Green Bay Oncology, Limited - Escanaba
		Jonathan Tammela	Ph:  800-432-6049
	Grand Rapids
	Gynecologic Oncology of West Michigan
		Gordon Downey, MD	Ph:  616-957-3398
	Iron Mountain
	Dickinson County Healthcare System
		Jonathan Tammela	Ph:  906-774-1313
	Kalamazoo
	Borgess Medical Center
		Raymond Lord, MD	Ph:  269-373-7458
	Bronson Methodist Hospital
		Raymond Lord, MD	Ph:  269-373-7458
	West Michigan Cancer Center
		Clinical Trials Office - West Michigan Cancer Center	Ph:  269-373-7458
	Royal Oak
	William Beaumont Hospital - Royal Oak Campus
		Clinical Trials Office - William Beaumont Hospital - Royal Oak Campus	Ph:  248-551-7695
	Saint Joseph
	Lakeside Cancer Specialists, PLLC
		Michael Rodriguez	Ph:  269-428-4411
	St. Joseph
	Lakeland Regional Cancer Care Center - St. Joseph
		Michael Rodriguez	Ph:  269-983-8698 800-303-8399
Minnesota
	Burnsville
	Fairview Ridges Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Coon Rapids
	Mercy and Unity Cancer Center at Mercy Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Edina
	Fairview Southdale Hospital
		Clinical Trials Office - Fairview Southdale Hospital	Ph:  612-625-3650
	Fridley
	Mercy and Unity Cancer Center at Unity Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Hutchinson
	Hutchinson Area Health Care
		Patrick Flynn, MD	Ph:  612-863-8585
	Maplewood
	HealthEast Cancer Care at St. John's Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Minnesota Oncology Hematology, PA - Maplewood
		Patrick Flynn, MD	Ph:  612-863-8585
	Minneapolis
	Hennepin County Medical Center - Minneapolis
		Clinical Trials Office - Hennepin County Medical Center - Minneapolis	Ph:  612-873-5911
	Masonic Cancer Center at University of Minnesota
		Clinical Trials Office - Masonic Cancer Center at University of Minnesota	Ph:  612-624-2620
	Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
		Clinical Trials Office - Virginia Piper Cancer Institute	Ph:  612-863-5654
	Robbinsdale
	Humphrey Cancer Center at North Memorial Outpatient Center
		Clinical Trials Office - Humphrey Cancer Center at North Memorial Outpatient Center	Ph:  763-520-1893
	Saint Louis Park
	CCOP - Metro-Minnesota
		Patrick Flynn, MD	Ph:  612-863-8585
	Park Nicollet Cancer Center
		Patrick Flynn, MD	Ph:  612-863-8585
	Saint Paul
	United Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Shakopee
	St. Francis Cancer Center at St. Francis Medical Center
		Patrick Flynn, MD	Ph:  612-863-8585
	St. Paul
	Regions Hospital Cancer Care Center
		Clinical Trials Office - Regions Hospital Cancer Care Center	Ph:  651-254-1517
	Stillwater
	Lakeview Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Waconia
	Ridgeview Medical Center
		Patrick Flynn, MD	Ph:  612-863-8585
	Willmar
	Willmar Cancer Center at Rice Memorial Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Woodbury
	Minnesota Oncology Hematology, PA - Woodbury
		Patrick Flynn, MD	Ph:  612-863-8585
Missouri
	Kansas City
	Heartland Hematology Oncology Associates, Incorporated
		Rakesh Gaur, MD	Ph:  913-948-5588
	North Kansas City Hospital
		Rakesh Gaur, MD	Ph:  913-948-5588
	Parvin Radiation Oncology
		Rakesh Gaur, MD	Ph:  913-948-5588
	Research Medical Center
		Rakesh Gaur, MD	Ph:  913-948-5588
	Saint Luke's Cancer Institute at Saint Luke's Hospital
		Rakesh Gaur, MD	Ph:  913-948-5588
	St. Joseph Medical Center
		Rakesh Gaur, MD	Ph:  913-948-5588
	Lee's Summit
	Saint Luke's East - Lee's Summit
		Rakesh Gaur, MD	Ph:  913-948-5588
	Liberty
	Liberty Hospital
		Rakesh Gaur, MD	Ph:  913-948-5588
	Saint Joseph
	Heartland Regional Medical Center
		Rakesh Gaur, MD	Ph:  913-948-5588
	Saint Joseph Oncology, Incorporated
		Rakesh Gaur, MD	Ph:  913-948-5588
	Saint Louis
	Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
		David Mutch, MD	Ph:  314-362-3181
	Springfield
	St. John's Regional Health Center
		Robert Carolla	Ph:  417-820-2000
Montana
	Billings
	Billings Clinic - Downtown
		Clinical Trials Office - Billings Clinic - Downtown	Ph:  800-996-2663
			Email: research@billingsclinic.org
Nebraska
	Omaha
	Methodist Estabrook Cancer Center
		Peter Morris, MD	Ph:  402-354-5250
	UNMC Eppley Cancer Center at the University of Nebraska Medical Center
		Clinical Trials Office - UNMC Eppley Cancer Center at the University of Nebraska Medical Center	Ph:  800-999-5465
New Mexico
	Albuquerque
	Southwest Gynecologic Oncology Associates, Incorporated
		Carolyn Muller, MD	Ph:  505-272-0185
	University of New Mexico Cancer Center
		Clinical Trials Office - University of New Mexico Cancer Center	Ph:  505-272-6972
	Las Cruces
	University of New Mexico Cancer Center - South
		Carolyn Muller, MD	Ph:  505-272-0185
New York
	Brightwaters
	Schwartz Gynecologic Oncology
		Benjamin Schwartz	Ph:  631-376-0055
Ohio
	Akron
	McDowell Cancer Center at Akron General Medical Center
		Daniel Guyton, MD	Ph:  330-344-6234
	Cleveland
	Case Comprehensive Cancer Center
		Clinical Trials Office - Case Comprehensive Cancer Center	Ph:  800-641-2422
	Cleveland Clinic Cancer Center at Fairview Hospital
		Clinical Trials Office - Cleveland Clinic Cancer Center at Fairview Hospital	Ph:  216-476-9362
	Cleveland Clinic Taussig Cancer Center
		Clinical Trials Office - Cleveland Clinic Taussig Cancer Center	Ph:  866-223-8100
	MetroHealth Cancer Care Center at MetroHealth Medical Center
		Peter Rose, MD	Ph:  216-444-1712
	Columbus
	Riverside Methodist Hospital Cancer Care
		Clinical Trials Office - Riverside Methodist Hospital Cancer Care	Ph:  614-566-4475
	Dayton
	David L. Rike Cancer Center at Miami Valley Hospital
		Clinical Trials Office - David L. Rike Cancer Center at Miami Valley Hospital	Ph:  937-208-2079
	Mayfield Heights
	Hillcrest Cancer Center at Hillcrest Hospital
		Peter Rose, MD	Ph:  216-444-1712
	Mentor
	Lake/University Ireland Cancer Center
		Steven Waggoner, MD	Ph:  216-844-5011
Oklahoma
	Oklahoma City
	Oklahoma University Cancer Institute
		Robert Mannel, MD	Ph:  405-271-8787
Pennsylvania
	Abington
	Rosenfeld Cancer Center at Abington Memorial Hospital
		Clinical Trials Office - Rosenfeld Cancer Center at Abington Memorial Hospital	Ph:  215-481-2402
	Allentown
	Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
		Richard Boulay, MD	Ph:  610-402-3650
	Bryn Mawr
	Bryn Mawr Hospital
		Clinical Trials Office - Bryn Mawr Hospital	Ph:  610-645-2680
	Paoli
	Cancer Center of Paoli Memorial Hospital
		Clinical Trials Office - Cancer Center of Paoli Memorial Hospital	Ph:  610-648-1637
	Pittsburgh
	UPMC Cancer Center at Magee-Womens Hospital
		Clinical Trials Office - UPMC Cancer Center at Magee-Womens Hospital	Ph:  412-647-2811
	Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
		Eileen Segreti, MD	Ph:  412-578-1116
	Wynnewood
	CCOP - Main Line Health
		Paul Gilman, MD	Ph:  610-645-2000
	Lankenau Cancer Center at Lankenau Hospital
		Paul Gilman, MD	Ph:  610-645-2000
Rhode Island
	Providence
	Women and Infants Hospital of Rhode Island
		Clinical Trials Office - Women and Infants Hospital of Rhode Island	Ph:  401-274-1122
South Carolina
	Charleston
	Hollings Cancer Center at Medical University of South Carolina
		Clinical Trials Office - Hollings Cancer Center at Medical University of South Carolina	Ph:  843-792-9321
Texas
	Houston
	Methodist Hospital
		Aparna Kamat	Ph:  713-441-1010
Virginia
	Richmond
	Virginia Commonwealth University Massey Cancer Center
		Clinical Trials Office -Virginia Commonwealth University Massey Cancer Center	Ph:  804-628-1939
Wisconsin
	Green Bay
	Green Bay Oncology, Limited at St. Mary's Hospital
		Jonathan Tammela	Ph:  920-884-3135
	Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
		Jonathan Tammela	Ph:  920-432-6049
	St. Mary's Hospital Medical Center - Green Bay
		Jonathan Tammela	Ph:  920-498-4200
	St. Vincent Hospital Regional Cancer Center
		Clinical Trials Office - St. Vincent Hospital Regional Cancer Center	Ph:  920-433-8889
	Madison
	University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
		Clinical Trials Office - University of Wisconsin Paul P. Carbone Comprehensive Cancer Center	Ph:  608-262-5223
	Manitowoc
	Holy Family Memorial Medical Center Cancer Care Center
		Clinical Trials Office - Holy Family Memorial Medical Center Cancer Care Center	Ph:  920-320-2749
	Marinette
	Bay Area Cancer Care Center at Bay Area Medical Center
		Jonathan Tammela	Ph:  715-735-6523 888-788-2070
	Marshfield
	Marshfield Clinic - Marshfield Center
		Clinical Trials Office - Marshfield Clinic - Marshfield Center	Ph:  800-782-1581 ext. 94457
	Milwaukee
	Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
		Clinical Trials Office - Vince Lombardi Cancer Clinic	Ph:  414-649-5717
	Minocqua
	Marshfield Clinic - Lakeland Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Oconto Falls
	Green Bay Oncology, Limited - Oconto Falls
		Jonathan Tammela	Ph:  920-846-3444 800-432-6049
	Rice Lake
	Marshfield Clinic - Indianhead Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Sturgeon Bay
	Green Bay Oncology, Limited - Sturgeon Bay
		Jonathan Tammela	Ph:  800-432-6049
	West Allis
	Aurora Women's Pavilion of West Allis Memorial Hospital
		Peter Johnson, MD (Contact information may not be current)	Ph:  262-549-6662
	Weston
	Marshfield Clinic - Weston Center
		Stuart Tipping, MD	Ph:  715-389-7549

Registry Information
Official Title		NURSE-DELIVERED WRITE SYMPTOMS© vs. SELF-DIRECTED WRITE SYMPTOMS© vs. CARE AS USUAL FOR OPTIMAL SYMPTOM MANAGEMENT FOR WOMEN WITH RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
Trial Start Date		2010-01-19
Trial Completion Date		2013-09-01 (estimated)
Registered in ClinicalTrials.gov		NCT00958698
Date Submitted to PDQ		2009-07-06
Information Last Verified		2012-02-07
NCI Grant/Contract Number		NR010735-01A1

Back to Top